SCHEMBL13250532

SCHEMBL13250532

Cc1ccc(C(c2cccc(CN3CCCNCc4cccc(n4)CNCCC3)c2)c2cccc(CN3CCCNCc4cccc(n4)CNCCC3)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 11/20 0.51
▸ CNR1 P21554 2/20 0.39
▸ CYP3A4 P08684 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ HPN P05981 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ DRD1 P21728 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ HRH2 P25021 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13250549 0.91 CXCR4 (0.62) CXCR4CHRM2CHRM1ADRA2CALDH1A1
SCHEMBL13250531 0.91 CXCR4 (0.55) CXCR4CHRM2CHRM1ADRA2CSMN1; SMN2
SCHEMBL13250533 0.89 CXCR4 (0.51) CXCR4CHRM2CHRM1ADRA2CSMN1; SMN2
SCHEMBL13250536 0.89 CXCR4 (0.51) CXCR4CNR1DRD2DRD4DRD3
SCHEMBL13250522 0.87 CXCR4 (0.46) CXCR4CNR1CYP3A4USP2CYP1A2
SCHEMBL13250537 0.86 CXCR4 (0.60) CXCR4CNR1CHRM2CHRM1ADRA2C
SCHEMBL13250487 0.84 CXCR4 (0.64) CXCR4CNR1CYP3A4USP2CYP1A2
SCHEMBL13250548 0.84 CXCR4 (0.65) CXCR4CHRM2CHRM1ADRA2CMEN1
SCHEMBL13250551 0.84 CXCR4 (0.63) CXCR4CHRM2CHRM1ADRA2CMEN1
SCHEMBL13250538 0.81 CXCR4 (0.49) CXCR4SLC6A2SLC6A4SLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
EP-2163553-A1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF Beijing Molecule Science and Technology Co., Ltd. (CN) 2010-03-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof SRM, SP1, SMS CXCR4 555/4885CNR1 1273/4885CYP3A4 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback